Editas Medicine IncNASDAQ:EDIT
- LAST PRICE4.7000
- TODAY'S CHANGE (%)0.0300 (0.6424%)
- Bid / Lots4.6900/ 10
- Ask / Lots4.7000/ 27
- Open / Previous Close4.6600 / 4.6700
- Day Range
- 52 Week Range
- Volume504,634
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EDIT |
|---|---|---|
| 09:32 ET | 32406 | 4.71 |
| 09:34 ET | 14481 | 4.73 |
| 09:36 ET | 17859 | 4.755 |
| 09:38 ET | 23697 | 4.805 |
| 09:39 ET | 14001 | 4.81 |
| 09:41 ET | 6055 | 4.8095 |
| 09:43 ET | 13680 | 4.7778 |
| 09:45 ET | 8519 | 4.76 |
| 09:48 ET | 13610 | 4.76 |
| 09:50 ET | 16174 | 4.78 |
| 09:52 ET | 5929 | 4.785 |
| 09:54 ET | 5150 | 4.7901 |
| 09:56 ET | 7783 | 4.78 |
| 09:57 ET | 14656 | 4.765 |
| 09:59 ET | 18893 | 4.795 |
| 10:01 ET | 15992 | 4.845 |
| 10:03 ET | 8439 | 4.795 |
| 10:06 ET | 1540 | 4.785 |
| 10:08 ET | 13643 | 4.7896 |
| 10:10 ET | 2125 | 4.795 |
| 10:12 ET | 5837 | 4.765 |
| 10:14 ET | 2699 | 4.78 |
| 10:15 ET | 7942 | 4.76 |
| 10:17 ET | 4438 | 4.755 |
| 10:19 ET | 8617 | 4.75 |
| 10:21 ET | 5881 | 4.735 |
| 10:24 ET | 6608 | 4.72 |
| 10:26 ET | 11349 | 4.73 |
| 10:28 ET | 3900 | 4.735 |
| 10:30 ET | 1547 | 4.735 |
| 10:32 ET | 2589 | 4.735 |
| 10:33 ET | 5667 | 4.72 |
| 10:35 ET | 5650 | 4.705 |
| 10:37 ET | 15019 | 4.68 |
| 10:39 ET | 10102 | 4.715 |
| 10:42 ET | 4512 | 4.695 |
| 10:44 ET | 3767 | 4.695 |
| 10:46 ET | 3415 | 4.68 |
| 10:48 ET | 8104 | 4.6801 |
| 10:50 ET | 6631 | 4.68 |
| 10:51 ET | 4282 | 4.685 |
| 10:53 ET | 5083 | 4.685 |
| 10:55 ET | 8179 | 4.68 |
| 10:57 ET | 2200 | 4.695 |
| 11:00 ET | 5200 | 4.704 |
| 11:02 ET | 2300 | 4.71 |
| 11:04 ET | 1378 | 4.705 |
| 11:06 ET | 700 | 4.705 |
| 11:08 ET | 5585 | 4.695 |
| 11:09 ET | 3200 | 4.695 |
| 11:11 ET | 1590 | 4.7 |
| 11:13 ET | 3090 | 4.71 |
| 11:15 ET | 4061 | 4.69 |
| 11:18 ET | 2950 | 4.695 |
| 11:20 ET | 2845 | 4.675 |
| 11:22 ET | 4322 | 4.685 |
| 11:24 ET | 3922 | 4.675 |
| 11:26 ET | 5428 | 4.695 |
| 11:27 ET | 5698 | 4.695 |
| 11:29 ET | 843 | 4.7 |
Jun 18, 2024
DJ Editas Medicine Is Maintained at Perform by Oppenheimer, from 12:57PM ET on Tuesday Jun 18, 2024 by Dow Jones
12:57PM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 14, 2024
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress, from 3:01AM ET on Friday Jun 14, 2024 by Dow Jones
3:01AM ET on Friday Jun 14, 2024 by Dow JonesEditas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress, from 3:00AM ET on Friday Jun 14, 2024 by Dow Jones
3:00AM ET on Friday Jun 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Editas Medicine Inc | 384.1M | -2.2x | --- |
Fate Therapeutics Inc | 373.4M | -1.7x | --- |
Alimera Sciences Inc | 291.3M | -3.5x | --- |
Enanta Pharmaceuticals Inc | 274.7M | -2.1x | --- |
ADC Therapeutics SA | 304.0M | -1.2x | --- |
Alector Inc | 437.6M | -3.2x | --- |
Company Information
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Contact Information
- Headquarters
- 11 Hurley StCAMBRIDGE, MA, United States 02141-2110
- Phone
- 617-401-9000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Emma Reeve
- President, Chief Executive Officer, Director
- Gilmore O'Neill
- Chief Financial Officer, Executive Vice President
- Erick Lucera
- Executive Vice President, Chief Scientific Officer
- Linda Burkly
- Senior Vice President, Chief Medical Officer
- Baisong Mei
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $384.1M |
|---|---|
Revenue (TTM) | $69.4M |
Shares Outstanding | 82.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.00 |
EPS | $-2.10 |
Book Value | $4.27 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -266.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
